Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
River Renal
New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
River 3 Renal Corp. has completed a Phase 2 study evaluating R3R01 in patients with Alport syndrome and focal segmental glomerulosclerosis. An ongoing Phase 2 trial is recruiting 60 patients to evaluate R3R01 for proteinuria excretion in diabetic kidney disease patients.
- Therapeutic areas
- Nephrology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
SR OneBain Capital Life SciencesHBM Healthcare InvestmentsPureos Bioventures
Beyond the preview
Go deeper on River Renal.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on River Renal.